StockData

Lexicon Pharmaceuticals vs Tonix Pharmaceuticals

LXRX and TNXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LXRX and TNXP compare

Lexicon Pharmaceuticals is the larger company, worth 16 times as much as Tonix Pharmaceuticals ($792M against $50.4M).

Tonix Pharmaceuticals grew revenue faster over the last twelve months (196% versus −29.0% for Lexicon Pharmaceuticals).

Lexicon Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −147% compared with −549% at Tonix Pharmaceuticals.

Tonix Pharmaceuticals scores higher on the StockData Score (10 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLXRXTNXP
Size and price
Market cap$792M$50.4M
Share price$1.78$2.94
Change, 1 year19.5%−81.5%
Change, 5 years−62.4%−100.0%
Beta (5Y)0.010.75
Employees81142
StockData Score
Total score510 (better)
Valuation score03 (better)
Growth score12 (better)
Performance score2 (better)0
Health score25 (better)
Dividend score00
Valuation
P/S19.1×1.7× (better)
P/B4.5×0.2× (better)
FCF yield–−314%
Fair value$0.950$16.91
Margin of safety−87.4%82.6% (better)
Growth
Revenue growth (TTM)−29.0%196% (better)
Revenue growth, 5Y average15.7%–
Profitability
Gross margin99.1% (better)83.8%
Operating margin−131% (better)−568%
Net margin−147% (better)−549%
FCF margin–−543%
Return on equity−40.2% (better)−81.8%
Return on invested capital−163% (better)−298%
Financial health
Debt / equity0.29 (better)0.00
Current ratio13.37 (better)6.61
Altman Z-score−4.87 (better)−5.42
Piotroski F-score46 (better)
Dividends and buybacks
Buyback yield–−427%
Shareholder yield0.00% (better)−427%
Ownership
Held by institutions81.9%54.6%
Held by insiders–0.27%
Insider net buying, 12 months$2.8M (better)$479K
Short interest, % of float–19.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.